Please login to the form below

Not currently logged in


This page shows the latest osimertinib news and features for those working in and with pharma, biotech and healthcare.

FDA approval gained, Pfizer sets sights on first-line NSCLC market

FDA approval gained, Pfizer sets sights on first-line NSCLC market

However, the real test of its mettle will come from AZ’s fast-growing Tagrisso (osimertinib) – billed as a third-generation inhibitor – which was approved in the US for first-line

Latest news

More from news
Approximately 5 fully matching, plus 36 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...